Recent events
Recent events tied to this brand in public sources.
Back to profile59 entries · Page 3 of 3
2020
FDA approves Roche’s Phesgo for HER2-positive breast cancer
The US Food and Drug Administration approved Roche’s Phesgo, a fixed-dose combination of Perjeta and Herceptin administered by subcutaneous injection, for treatment of early and metastatic HER2-positive breast cancer.
2020
Innovent and Roche enter strategic collaboration
Innovent Biologics, through its wholly owned subsidiary Innovent Biologics (HK) Limited, entered a strategic collaboration with Roche focused on research, clinical development and commercialization of bispecific antibody and cell therapy products.
2020
Innovent and Roche announce strategic collaboration
Innovent Biologics (HK) Limited, a wholly owned subsidiary of Innovent Biologics, and Roche Group announced a strategic collaboration to discover and develop multiple cell therapy and bispecific antibody products.
2020
FDA approves Tecentriq and Avastin combination for liver cancer
Roche announced that the US Food and Drug Administration approved Tecentriq in combination with Avastin for people with unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy.
2020
Roche acquires Stratos Genomics
Roche announced that it had acquired Stratos Genomics, an early-stage sequencing technology company, to advance development of Roche's nanopore sequencer. The acquisition gives Roche access to Stratos Genomics' Sequencing by Expansion chemistry.
2020
Roche and Vividion enter an exclusive worldwide option and license agreement
Roche signed an exclusive worldwide option and license agreement with Vividion Therapeutics for access to its proteomics screening platform and small molecule library and the option to license compounds arising from selected programmes.
2020
RxMx and Roche's multiple sclerosis app wins a MedTech Breakthrough Award
An app designed by RxMx Corp together with Roche to help people with multiple sclerosis manage their condition won a MedTech Breakthrough Award in the Patient Engagement Innovation category.
2020
FDA approves Xolair prefilled syringe for self-injection across indications
Roche announced that the U.S. Food and Drug Administration approved its supplemental Biologics License Application for Xolair prefilled syringe for self-injection across all approved U.S. indications.
2020
Roche and Arrakis enter drug discovery collaboration
Roche and Arrakis Therapeutics entered into a strategic collaboration and license agreement to discover RNA-targeted small molecule drugs against targets across Roche’s research and development areas.
2020
Roche launches Atezolizumab in India
Roche India said it had launched Atezolizumab in India for metastatic triple-negative breast cancer after receiving approval from the Indian drug regulator.
2020
Spring Bank and Roche announce clinical collaboration on SB 11285
Spring Bank Pharmaceuticals announced a clinical collaboration with Roche to explore co-administration of SB 11285 and Roche's atezolizumab (Tecentriq) in patients with advanced solid tumors.
2020
Roche completes acquisition of Promedior
Promedior announced the completion of its sale to Roche. Roche obtained full rights to Promedior's portfolio of molecules for serious fibrotic diseases, including PRM-151.
2020
Romania fines Roche over alleged anti-competitive conduct involving cancer medicines
Romanian antitrust authorities fined Roche $14 million for tactics they said impeded competition to two cancer medicines. The article reports allegations involving pricing to distributors bidding to supply a national cancer-medicines program and hospitals.
2019
Roche completes acquisition of Spark Therapeutics
Roche completed its acquisition of Spark Therapeutics after Spark accepted a tender offer for all outstanding common shares at $114.50 per share. Spark became a wholly owned subsidiary of Roche, and its shares would no longer be traded on Nasdaq.
2019
Regulators close investigation into Roche's acquisition of Spark Therapeutics
The U.S. Federal Trade Commission and the U.K. Competition and Markets Authority closed their 10-month investigation into Roche's acquisition of Spark Therapeutics and whether it would harm competition in the hemophilia A treatment space.
2019
UK regulator clears Roche's acquisition of Spark Therapeutics
The UK Competition and Markets Authority cleared Roche's $4.3 billion acquisition of Spark Therapeutics. The deal still required US regulatory approval.
2019
Regulators approve Roche-Spark acquisition
The U.K. Competition and Markets Authority and the U.S. Federal Trade Commission approved the Roche-Spark acquisition on Monday, clearing the remaining regulatory hurdles described in the report.
2019
FDA approves Tecentriq combination as initial treatment for metastatic non-squamous NSCLC
The US Food and Drug Administration approved Roche’s Tecentriq in combination with Abraxane and carboplatin as an initial treatment for adults with metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic tumour aberrations.
2019
Drugmakers agree to reduce prices of some medicines in China
Chinese regulators said pharmaceutical companies, including Roche and Novartis, agreed to reduce the China prices of some newer medicines by an average of 61% to enter the national medical insurance reimbursement list.